Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Decrement in Hemoglobin Levels Is Indicative of Colorectal Cancer

By LabMedica International staff writers
Posted on 19 Aug 2010
Long-term variation in blood hemoglobin (Hb) levels could detect subtle gastrointestinal bleeding in the early development of colorectal cancer (CRC). More...


Anemia, a common blood disorder, is characterized by low Hb levels, and has long been associated with those suffering from CRC. A sharp decrease in Hb levels was thought to be a symptom of colon cancer.

In a recent study carried out at the School of Public Health, Tel Aviv University (Tel Aviv, Israel), a total of 1,074 CRC cases aged 45–75 years that had been diagnosed with CRC and had normal Hb levels were frequency matched for age and sex with cancer-free individuals at a ratio of 10 controls per case. In this retrospective study, the scientists looked at data from each participant's blood tests over a ten-year period, retrieved from a computerized database.

The scientists have discovered that it is the continuous long-term decline that may announce the onset of cancer. Though hemoglobin levels may vary in every human being as a result of aging, a distinct trend was discovered among study participants who had been diagnosed with colorectal cancer during the study period. Approximately four years prior to their diagnoses, their blood tests began to show a continuous decline in Hb levels. A declining trend of more than 0.28 g/dL every six months over a four-year period was observed and it may serve as a warning of illness on the horizon. CRC patients were characterized by an on-going, long-term, logarithmic decrement in Hb levels. Such small changes within the normal Hb range could be missed by health providers, but automatically detected by computerized alert algorithms. Participants of the study with colorectal cancer experienced a sharp decline in Hb levels, but because the declines did not put them outside the normal range, no red flags were raised.

Inbal Goldshtein, a graduate student and lead author of the study said, "In practice, a doctor will look at the final results and see if the hemoglobin levels are within a normal range, but this is not accurate enough. It is important to look at the continuing trend of each individual. If a person experiences a consistent decline relative to his own average level, it may be cause for concern." The study was published in the July 2010 issue of the European Journal of Cancer Prevention.

The benefit of this screening process is that can be part of an average physical. Current testing for colorectal cancer is often expensive and unpleasant and there is also a very low compliance rate among patients. The next step is to create an algorithm, which will automatically detect suspicious declines in Hb levels, advising physicians to send their patients for further testing. More than 50,000 people in the U.S.A. will die from colon cancer in 2010, but better screening could significantly reduce those numbers.

Related Links:

Tel Aviv University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The MyChoice CDx test, currently used as a companion diagnostic in ovarian cancer, will generate the PrGIS score and is being advanced for use in prostate cancer. (Photo courtesy of Myriad Genetics)

Collaboration Advances Genomic Instability Biomarker for Prostate Cancer

In prostate cancer, homologous recombination deficiency is emerging as an important prognostic and predictive biomarker. Measuring the chromosomal instability associated with this pathway may help guide... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.